Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Net Margin: 2013-2017

Historic Net Margin for Soleno Therapeutics (SLNO) over the last 3 years, with Jun 2017 value amounting to -91,300.00%.

  • Soleno Therapeutics' Net Margin fell 3050000.00% to -91,300.00% in Q2 2017 from the same period last year, while for Jun 2017 it was -1,225.48%, marking a year-over-year increase of 1365.00%. This contributed to the annual value of 76,125.54% for FY2024, which is N/A change from last year.
  • According to the latest figures from Q2 2017, Soleno Therapeutics' Net Margin is -91,300.00%, which was down 28,634.56% from -317.74% recorded in Q1 2017.
  • Soleno Therapeutics' 5-year Net Margin high stood at 295.07% for Q2 2014, and its period low was -91,300.00% during Q2 2017.
  • In the last 3 years, Soleno Therapeutics' Net Margin had a median value of -1,639.40% in 2015 and averaged -17,291.91%.
  • Data for Soleno Therapeutics' Net Margin shows a peak YoY increase of 1,007,813bps (in 2016) and a maximum YoY decrease of 5,766,186bps (in 2016) over the last 5 years.
  • Over the past 5 years, Soleno Therapeutics' Net Margin (Quarterly) stood at 280.17% in 2013, then tumbled by 10,063bps to 179.54% in 2014, then slumped by 135,754bps to -1,178.00% in 2015, then surged by 25,711bps to -920.89% in 2016, then slumped by 3,050,000bps to -91,300.00% in 2017.
  • Its Net Margin was -91,300.00% in Q2 2017, compared to -317.74% in Q1 2017 and -920.89% in Q4 2016.